Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study

Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study

Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palb...

Full description

Bibliographic Details
Main Authors: Katie Mycock, Lin Zhan, Gavin Taylor-Stokes, Gary Milligan, Debanjali Mitra
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Current Oncology
Subjects:
palbociclib
Canada
metastatic breast cancer
real-world
retrospective
medical chart review
Online Access:https://www.mdpi.com/1718-7729/28/1/66

Internet

https://www.mdpi.com/1718-7729/28/1/66

Similar Items